Fresenius Kabi's ustekinumab biosimilar Otulfi ™ is now commercially available for both subcutaneous and intravenous formulations With this launch, Fresenius Kabi Canada's immunology biosimilar ...

Fresenius Kabi received Health Canada's Notice of Compliance (NOC) approval for Iodixanol injection on December 17 for both intravenous and intra-arterial administration With the launch of Iodixanol ...

Director and Head of Commercial, Fresenius Kabi Biopharma, Canada. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role ...

Fresenius operates through two main business segments, Fresenius Kabi and Fresenius Helios. It owns investments in other healthcare businesses, most notably Fresenius Medical Care. Fresenius Kabi ...

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...

Vifor Pharma has forged a strategic partnership with Fresenius Kabi, focusing on marketing a portfolio of iron deficiency drugs. The partnership expands Vifor Pharma’s cooperation with Fresenius ...

Aurora™ is the automated system that streamlines plasma collection, producing virtually cell-free plasma and providing an improved experience for both operators and donors. The system separates ...

Fresenius (FMS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

Drinking water—even before bed—can help prevent symptoms of dehydration like headaches or fatigue,” he says.He also adds that at night, our bodies regulate the hormone vasopressin ...

BAD HOMBURG, Germany, June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second ...